Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 7996 AL 8010

Current Developments in Alzheimer's Disease

Goetzl EJ.

Am J Med. 2025 Jan;138(1):15-20. doi: 10.1016/j.amjmed.2024.08.019. Epub 2024 Aug 27.

Low-dose interleukin-2 in patients with mild to moderate Alzheimer's disease: a randomized clinical trial

Faridar A, Gamez N, Li D, Wang Y, Boradia R, Thome AD, Zhao W, Beers DR, Thonhoff JR, Nakawah MO, Román GC, Volpi JJ, Toledo JB, George M, Davis CS, Pascual B, Grundman M, Masdeu JC, Appel SH.

Alzheimers Res Ther. 2025 Jul 4;17(1):146. doi: 10.1186/s13195-025-01791-x.

Towards pharmacological prevention of Alzheimer disease

Llibre-Guerra JJ, McDade EM, Schindler SE, Clifford DB, Supnet C, Atri A, Bateman RJ.

Nat Rev Neurol. 2025 Dec;21(12):721-733. doi: 10.1038/s41582-025-01154-y. Epub 2025 Nov 3.

Spotlight on Alzheimer's disease and related dementias research in East Asia

Le W, Shen L, Guo T, Xie F.

Alzheimers Dement. 2025 Jul;21(7):e70479. doi: 10.1002/alz.70479.

Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study

Zúñiga CH, Acosta BI, Menchaca R, Amescua CA, Hong S, Hui L, Gil M, Rhee YH, Yoon S, Kim M, Chang PY, Kim YM, Song PY, Betito K.

Alzheimers Res Ther. 2025 Feb 12;17(1):40. doi: 10.1186/s13195-025-01681-2.

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

McDade EM, Barthélemy NR, Wang G, Li Y, Cao Y, Gordon B, Benzinger TLS, Clifford D, Goate AM, Renton AE, Hassenstab J, Llibre-Guerra JJ, Perrin RJ, Xiong C, Cruchaga C, Mummery CJ, Berman SB, Lah J, Roberson ED, Van Dyck C, Gauthier S, Masters CL, Masellis M, Bittner T, Yaari R, Chhatwal J, Chrem P, Brooks W, Suzuki K, Levin JJ, Jucker M, Ringman J, Wallon D, Ikeuchi T, Lee JH, Roh JH, Schofield P, Fox NC, Ryan NS, Vöglein J, Karch C, Ibáñez L, Day GS, Sánchez-Valle R, Daniels A, Morris JC, Supnet-Bell C, Levey AI, Bateman RJ; DIAN‐TU Study Team and DIAN Obs Team.

Alzheimers Dement. 2025 Sep;21(9):e70689. doi: 10.1002/alz.70689.

Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China

Chen S, Ou R, Wei Q, Li C, Song W, Zhao B, Yang J, Fu J, Ma Y, Liu J, Wang X, Fang D, Hu T, Xiao L, Zhang S, Huang R, Guo X, Feng F, Chen X, Shang H.

Alzheimers Dement. 2025 Oct;21(10):e70750. doi: 10.1002/alz.70750.

Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer's Disease

Liu X, Baxley S, Hebron M, Turner RS, Moussa C.

Int J Mol Sci. 2025 May 23;26(11):5044. doi: 10.3390/ijms26115044.

Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Lu M, Kim MJ, Collins EC, Shcherbinin S, Ellinwood AK, Yokoi Y, Brooks DA, Hansson O, Knopman DS, Sims JR, Mintun MA.

JAMA Neurol. 2025 Dec 1;82(12):1251-1256. doi: 10.1001/jamaneurol.2025.3869.

Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics

Villain N, Planche V, Lilamand M, Cordonnier C, Soto-Martin M, Mollion H, Bombois S, Delrieu J; French Federation of Memory Clinics Work Group on Anti-Amyloid Immunotherapies.

J Prev Alzheimers Dis. 2025 Apr;12(4):100094. doi: 10.1016/j.tjpad.2025.100094. Epub 2025 Feb 25.

Pathological mechanisms and treatment progression of Alzheimer's disease

Zhang J, Kong G, Yang J, Pang L, Li X.

Eur J Med Res. 2025 Jul 14;30(1):625. doi: 10.1186/s40001-025-02886-9.

Alzheimer disease seen through the lens of sex and gender

Castro-Aldrete L, Einsiedler M, Novakova Martinkova J, Depypere H, Alvin Ang TF, Mielke MM, Sindi S, Eyre HA, Au R, Schumacher Dimech AM, Dé A, Szoeke C, Tartaglia MC, Santuccione Chadha A.

Nat Rev Neurol. 2025 May;21(5):235-249. doi: 10.1038/s41582-025-01071-0. Epub 2025 Apr 14.

TREM2 and sTREM2 in Alzheimer's disease: from mechanisms to therapies

Zhang L, Xiang X, Li Y, Bu G, Chen XF.

Mol Neurodegener. 2025 Apr 17;20(1):43. doi: 10.1186/s13024-025-00834-z.

Pathogenesis of comorbid epilepsy in Alzheimer's disease and use of perampanel, an AMPA receptor inhibitor

Kuzuya A, Ohara T, Akamatsu N.

Expert Rev Neurother. 2025 Dec;25(12):1399-1409. doi: 10.1080/14737175.2025.2581758. Epub 2025 Oct 30.

Alzheimer, Parkinson, dementia, and phytochemicals: insight review

Can B, Sanlier N.

Crit Rev Food Sci Nutr. 2025;65(9):1706-1728. doi: 10.1080/10408398.2023.2299340. Epub 2024 Jan 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias